These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25304034)

  • 1. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis.
    Fu W; Guo H; Guo J; Lin K; Wang H; Zhang Y; Wang Y; Shan Z
    J Cardiovasc Med (Hagerstown); 2014 Dec; 15(12):873-9. PubMed ID: 25304034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis.
    Antza C; Doundoulakis I; Akrivos E; Economou F; Vazakidis P; Haidich AB; Kotsis V
    Scand Cardiovasc J; 2019 Apr; 53(2):48-54. PubMed ID: 30896311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
    Wang X; Wang T; Chen X; Tian W; Ma D; Zhang J; Li Q; Chen Z; Ju J; Xu H; Chen K
    J Am Med Dir Assoc; 2023 Aug; 24(8):1233-1239.e26. PubMed ID: 37355246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation.
    Aronow WS; Shamliyan TA
    Am J Ther; 2020; 27(3):e270-e285. PubMed ID: 30277905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
    Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
    Morimoto T; Crawford B; Wada K; Ueda S
    J Cardiol; 2015 Dec; 66(6):466-74. PubMed ID: 26162944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Non-Vitamin K Anticoagulants for Atrial Fibrillation in Relation to Different Renal Function Levels: A Network Meta-Analysis.
    Jin H; Zhu K; Wang L; Li Y; Meng J; Zhi H
    Cardiovasc Ther; 2020; 2020():2683740. PubMed ID: 32405322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.
    Dogliotti A; Paolasso E; Giugliano RP
    Clin Cardiol; 2013 Feb; 36(2):61-7. PubMed ID: 23338902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.
    Camm AJ; Fox KAA; Peterson E
    Europace; 2018 Jan; 20(1):1-11. PubMed ID: 29040518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
    López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
    BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
    [No Abstract]   [Full Text] [Related]  

  • 18. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations.
    Stacy ZA; Richter SK
    Ther Adv Cardiovasc Dis; 2018 Sep; 12(9):247-262. PubMed ID: 30081727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.